Evonik stock: BASF calls tie-up optional, says it will not overpay

Evonik stock remains caught between a reported higher BASF approach and the absence of a confirmed transaction. On October 28, BASF CEO Markus Kamieth said a potential combination would have to create value for BASF shareholders and that the group would not overpay, according to Reuters. That statement adds a condition to a takeover story that remains unresolved.

What has changed since the last report

Reuters reported on October 23 that BASF had raised its reported offer to EUR 24.00 per Evonik share, valuing the target at about EUR 11.18 billion. The figure came from two people close to the deal; Evonik and its largest shareholder, the RAG Foundation, declined to comment. The reported approach therefore remains separate from a formal offer, an agreement or a completed transaction.

Kamieth described the potential transaction as one BASF could pursue, rather than a necessity. For investors, that distinction limits what can be inferred from the reported price: the figure provides a reference point for valuation, but it does not establish that Evonik will enter negotiations or that shareholders will receive the reported amount.

Next operating checkpoint

Evonik's investor-relations calendar lists November 3, 2026, for reporting on the third quarter. The scheduled release will provide the next company-specific test of operating performance, separate from the takeover discussion. The company had previously published second-quarter adjusted EBITDA of EUR 630 million and full-year adjusted EBITDA guidance of EUR 2.0 billion to EUR 2.2 billion, as reported on its investor-relations page.

At 16:30:55 Berlin time on October 29, Lang & Schwarz showed Evonik at EUR 21.14. That was 0.56 percent below the verified Xetra close of EUR 21.26 on October 28. The comparison is a market snapshot and does not establish a causal reaction to BASF's comments.

Investors can follow the real-time quote of Evonik stock.

The broader market backdrop can be followed in the DAX market overview.

More news and analyses on Evonik stock.